Evidence map›Paper›PMID 20802517›Full record

ArticleOncogene2010

DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway.

S Ocak, H Yamashita, A R Udyavar, A N Miller, A L Gonzalez, Y Zou, A Jiang, Y Yi, Y Shyr, L Estrada and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Oncogene, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Clinical Significance and Potential Role ofFrontiers in genetics · 2021
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

S OcakDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University, Nashville, TN 37232-6838, USA.
H Yamashita
A R Udyavar
A N Miller
A L Gonzalez
Y Zou
A Jiang
Y Yi
Y Shyr
L Estrada
V Quaranta
P P Massion
Vanderbilt University · USU-M Rogel Cancer CenterVeterans Health Administration · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
TrainingU54CA113007 · NCI · VANDERBILT UNIVERSITY · PI ESTRADA-RODGERS, LOURDES · 2004 to 2014
$19.2M
Intramural VA VA999999NCI NIH HHS 5P30 CA068485NCI NIH HHS P30 CA068485NCI NIH HHS U54 CA113007
6 · The paper itself

Abstract

Small-cell lung cancer (SCLC) is the most aggressive subtype of lung cancer in its clinical behavior, with a 5-year overall survival as low as 5%. Despite years of research in the field, molecular determinants of SCLC behavior are still poorly understood, and this deficiency has translated into an absence of specific diagnostics and targeted therapeutics. We hypothesized that tumor DNA copy number alterations would allow the identification of molecular pathways involved in SCLC progression. Array comparative genomic hybridization was performed on DNA extracted from 46 formalin-fixed paraffin-embedded SCLC tissue specimens. Genomic profiling of tumor and sex-matched control DNA allowed the identification of 70 regions of copy number gain and 55 regions of copy number loss. Using molecular pathway analysis, we found a strong enrichment in these regions of copy number alterations for 11 genes associated with the focal adhesion pathway. We verified these findings at the genomic, gene expression and protein level. Focal Adhesion Kinase (FAK), one of the central genes represented in this pathway, was commonly expressed in SCLC tumors and constitutively phosphorylated in SCLC cell lines. Those were poorly adherent to most substrates but not to laminin-322. Inhibition of FAK phosphorylation at Tyr(397) by a small-molecule inhibitor, PF-573,228, induced a dose-dependent decrease of adhesion and an increase of spreading in SCLC cell lines on laminin-322. Cells that tended to spread also showed a decrease in focal adhesions, as demonstrated by a decreased vinculin expression. These results support the concept that pathway analysis of genes in regions of copy number alterations may uncover molecular mechanisms of disease progression and demonstrate a new role of FAK and associated adhesion pathways in SCLC. Further investigations of FAK at the functional level may lead to a better understanding of SCLC progression and may have therapeutic implications.

Indexed as

Focal AdhesionsGene DosageCarcinoma, Small CellCell AdhesionCell Line, TumorComparative Genomic HybridizationFocal Adhesion Protein-Tyrosine KinasesHumansLung NeoplasmsQuinolonesSulfones6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-oneFocal Adhesion Protein-Tyrosine KinasesQuinolonesSulfones

Identifiers

PMID20802517
PMCPMC4637980
OpenAlexW2047622372

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.